



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

E3 Ligase Ligand-Linker Conjugates


E3 Ligase Ligand-Linker Conjugate, which is one part of Proteolysis Targeting Chimeric Molecules (PROTACs), incorporates a ligand for the E3 ubiquitin ligase and a linker. After linked to the ligand for target protein (such as JQ1 for BRD4 protein, Molibresib for BET protein), those conjugates can be used for constituting PROTACs that target protein for ubiquitination and degradation. Currently, several PROTACs have been found to show good biological activity by specifically targeting BET, estrogen receptor (ER), androgen receptor, etc. MedChemExpress (MCE) offers a wide range of high quality E3 Ligase Ligand-Linker Conjugates including von Hippel-Lindau (VHL) ligands, MDM2 ligands, Cereblon (CRBN) ligands and cIAP1 ligands conjugating with different linkers (PEGs, Alkyl-Chain, Alkyl/ether, etc.). It's convenient and time-saving for designing and synthesizing a wide variety of novel PROTACs (ARV-825, dBET1, MT-802, etc.), which can expand the application of PROTACs in the treatment of cancer, autoimmunity, inflammation and other diseases.

E3 Ligase Ligand-Linker Conjugates Chemicals

(S,R,S)-AHPC-(C3-PEG)2-C6-Cl (VHL Ligand-Linker Conjugates 11; E3 ligase Ligand-Linker Conjugates 11)

Cat. No.: HY-103608

(S,R,S)-AHPC-(C3-PEG)2-C6-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker. (S,R,S)-AHPC-(C3-PEG)2-C6-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.




Purity: 99.89%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-amido-C5-acid

Cat. No.: HY-130798

(S,R,S)-AHPC-amido-C5-acid incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-amido-C5-acid can be used to design XY028-133 (HY-129180).




Purity: 97.84%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

(S,R,S)-AHPC-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH

(VH032-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH) Cat. No.: HY-131168

(S,R,S)-AHPC-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH (VH032-Boc-trans-3-aminocyclobutanol-Pip-CH2COOH) is a E3 ligase ligand-linker conjugate that contains on one end a VHL ligand.




Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

(S,R,S)-AHPC-C1-Br

Cat. No.: HY-138862

(S,R,S)-AHPC-C1-Br is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C1-NH2

Cat. No.: HY-138861

(S,R,S)-AHPC-C1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(S,R,S)-AHPC-C1-NH2 hydrochloride

Cat. No.: HY-138861A

(S,R,S)-AHPC-C1-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C10-NH2

(VH032-C10-NH2) Cat. No.: HY-129941

(S,R,S)-AHPC-C10-NH2 (VH032-C10-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for BET-Targeted PROTAC.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C10-NH2 dihydrochloride

(VH032-C10-NH2 dihydrochloride) Cat. No.: HY-129941A

(S,R,S)-AHPC-C10-NH2 dihydrochloride (VH032-C10-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for BET-Targeted PROTAC.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C2-NH2

Cat. No.: HY-136163A

(S,R,S)-AHPC-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C2-NH2 dihydrochloride

Cat. No.: HY-136163


(S,R,S)-AHPC-C2-NH2 dihydrochloride incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-OH can be used in the synthesis of a series of PROTACs.



Purity: 98.85%
Clinical Data: No Development Reported
Size: 25 mg

(S,R,S)-AHPC-C2-PEG4-N3**(VH032-C2-PEG4-N3)****Cat. No.:** HY-130654


(S,R,S)-AHPC-C2-PEG4-N3 (VH032-C2-PEG4-N3) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C3-NH2**(VH032-C3-NH2)****Cat. No.:** HY-130711


(S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C3-NH2 hydrochloride**(VH032-C3-NH2 hydrochloride)****Cat. No.:** HY-130711B


(S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) hydrochloride is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

(S,R,S)-AHPC-C3-NH2 TFA**(VH032-C3-NH2 TFA)****Cat. No.:** HY-130711A


(S,R,S)-AHPC-C3-NH2 TFA (VH032-C3-NH2 TFA) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C4-NH2**(VH032-C4-NH2)****Cat. No.:** HY-114176A


(S,R,S)-AHPC-C4-NH2 is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C4-NH2 dihydrochloride**(VH032-C4-NH2 dihydrochloride)****Cat. No.:** HY-114176B


(S,R,S)-AHPC-C4-NH2 dihydrochloride is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C4-NH2 hydrochloride (VH032-C4-NH2 hydrochloride; VHL Ligand-Linker Conjugates 13; ...)**Cat. No.:** HY-114176


(S,R,S)-AHPC-C4-NH2 hydrochloride is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.



Purity: 95.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-C5-COOH**(VH032-C5-COOH)****Cat. No.:** HY-136055


(S,R,S)-AHPC-C5-COOH (VH032-C5-COOH) is a synthesized **E3 ligase ligand-linker conjugate**, contains the VH032 VHL-based ligand and a linker to form PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

(S,R,S)-AHPC-C5-NH2**(VH032-C5-NH2)****Cat. No.:** HY-136187


(S,R,S)-AHPC-C5-NH2 (VH032-C5-NH2) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for estrogen-related receptor α (ERR α) PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C6-NH2**(VH032-C6-NH2)****Cat. No.:** HY-136006B

(S,R,S)-AHPC-C6-NH2 (VH032-C6-NH2) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.




Purity: 96.64%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg

(S,R,S)-AHPC-C6-NH2 dihydrochloride
(VH032-C6-NH2 dihydrochloride)

Cat. No.: HY-136006

(S,R,S)-AHPC-C6-NH2 dihydrochloride (VH032-C6-NH2 dihydrochloride) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C6-NH2 hydrochloride
(VH032-C6-NH2 hydrochloride)

Cat. No.: HY-136006A

(S,R,S)-AHPC-C6-NH2 hydrochloride (VH032-C6-NH2 hydrochloride) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C6-PEG3-C4-Cl (VH032-C6-PEG3-C4-Cl; VHL
Ligand-Linker Conjugates 12; ...)

Cat. No.: HY-103605

(S,R,S)-AHPC-C6-PEG3-C4-Cl (VH032-C6-PEG3-C4-Cl) is a conjugate of ligands for E3 and 20-atom-length linker. The connector of linker is Halogen group.




Purity: 95.46%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-C7-amine
(VH032-C7-amine)

Cat. No.: HY-136186

(S,R,S)-AHPC-C7-amine (VH032-C7-amine) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for estrogen-related receptor α (ERR α) PROTAC degrader.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C8-NH2
(VH032-C8-NH2)

Cat. No.: HY-133487B

(S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1.




Purity: 95.07%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

(S,R,S)-AHPC-C8-NH2 dihydrochloride
(VH032-C8-NH2 dihydrochloride)

Cat. No.: HY-133487

(S,R,S)-AHPC-C8-NH2 dihydrochloride (VH032-C8-NH2 dihydrochloride) is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-C8-NH2 hydrochloride
(VH032-C8-NH2 hydrochloride)

Cat. No.: HY-133487A

(S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) hydrochloride is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-CO-C9-acid
(VH032-NH-CO-C9-acid)

Cat. No.: HY-139345

(S,R,S)-AHPC-CO-C9-acid is an **E3 ligase ligand-linker conjugate** that can be connected to the ligand for protein to form PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-Me-C10-Br

Cat. No.: HY-130642

(S,R,S)-AHPC-Me-C10-Br is a synthesized **E3 ligase ligand-linker conjugate**. (S,R,S)-AHPC-Me-C10-Br incorporates a VHL E3 ligase linker and MS432 based on the MEK1/2 inhibitor PD0325901.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-Me-C10-NH2

Cat. No.: HY-130847

(S,R,S)-AHPC-Me-C10-NH2 is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-C10-NH2 can be used in PROTAC MS432 (HY-130602).




Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 500 mg

(S,R,S)-AHPC-Me-C5-COOH

Cat. No.: HY-130849

(S,R,S)-AHPC-Me-C5-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-C5-COOH can be used in PROTAC DT2216 (HY-130604).




Purity: 96.19%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

(S,R,S)-AHPC-Me-C7 ester

Cat. No.: HY-130640

(S,R,S)-AHPC-Me-C7 ester is a E3 ligase ligand-linker conjugate used to synthesise BCL-X_L PROTAC degraders.




Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

(S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2

Cat. No.: HY-131387

(S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2 can be used in PROTAC BRD4 Degrader-5 (HY-133737) and PROTAC BRD4 Degrader-5-CO-PEG3-N3 (HY-133736).




Purity: 95.06%
Clinical Data: No Development Reported
Size: 25 mg, 100 mg

(S,R,S)-AHPC-Me-decanedioic acid

Cat. No.: HY-132938

(S,R,S)-AHPC-Me-decanedioic acid is an E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-O-Ph-PEG1-NH-Boc

(VH032-O-Ph-PEG1-NH-Boc)

Cat. No.: HY-130638

(S,R,S)-AHPC-O-Ph-PEG1-NH-Boc (VH032-O-Ph-PEG1-NH-Boc) is a synthesized E3 ligase ligand-linker conjugate which is used for the EED-targeted PROTAC.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-O-Ph-PEG1-NH2

(VH032-O-Ph-PEG1-NH2)

Cat. No.: HY-130816

(S,R,S)-AHPC-O-Ph-PEG1-NH2 (VH032-O-Ph-PEG1-NH2) is E3 ligase ligand-linker conjugate and incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-O-Ph-PEG1-NH2 is used in PROTAC EED degrader-1 (HY-130614).




Purity: 96.97%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg

(S,R,S)-AHPC-PEG1-N3 (VH032-PEG1-N3; VHL Ligand-Linker

Conjugates 9; E3 ligase Ligand-Linker Conjugates 3)

Cat. No.: HY-103600

(S,R,S)-AHPC-PEG1-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 1-unit PEG linker used in PROTAC technology.




Purity: 98.41%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-PEG1-NH2

(VH032-PEG1-NH2)

Cat. No.: HY-136008

(S,R,S)-AHPC-PEG1-NH2 (VH032-PEG1-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

(S,R,S)-AHPC-PEG1-NH2 dihydrochloride

(VH032-PEG1-NH2 dihydrochloride)

Cat. No.: HY-136008A

(S,R,S)-AHPC-PEG1-NH2 (VH032-PEG1-NH2) dihydrochloride incorporates a VHL ligand for the E3 ubiquitin ligase and a PROTAC linker. (S,R,S)-AHPC-PEG1-NH2 dihydrochloride can be used to design PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-PEG1-OTs (VH032-PEG1-OTs; VHL Ligand-Linker

Conjugates 2; E3 ligase Ligand-Linker Conjugates 51)

Cat. No.: HY-125846


(S,R,S)-AHPC-PEG1-OTs is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 1-unit PEG linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 2 g

(S,R,S)-AHPC-PEG2-C4-Cl (VH032-PEG2-C4-Cl; VHL Ligand-Linker Conjugates 7; E3 ligase Ligand-Linker Conjugates 10) Cat. No.: HY-103607


(S,R,S)-AHPC-PEG2-C4-Cl (VH032-PEG2-C4-Cl) is a conjugate of ligands for E3 and 13-atom-length linker. The connector of linker is Halogen group. (S,R,S)-AHPC-PEG2-C4-Cl incorporates the (S,R,S)-AHPC based VHL ligand and an alkyl/ether-based linker.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-PEG2-N3 (VH032-PEG2-N3; VHL Ligand-Linker Conjugates 6; E3 ligase Ligand-Linker Conjugates 13) Cat. No.: HY-103599


(S,R,S)-AHPC-PEG2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in PROTAC technology.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-PEG2-NH2 (VH032-PEG2-NH2; VHL Ligand-Linker Conjugates 3; ...) Cat. No.: HY-103603A


(S,R,S)-AHPC-PEG2-NH2 (VH032-PEG2-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-PEG2-NH2 dihydrochloride (VH032-PEG2-NH2 dihydrochloride) Cat. No.: HY-103603B


(S,R,S)-AHPC-PEG2-NH2 dihydrochloride (VH032-PEG2-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-PEG2-NH2 hydrochloride (VH032-PEG2-NH2 hydrochloride; ...) Cat. No.: HY-103603


(S,R,S)-AHPC-PEG2-NH2 hydrochloride (VH032-PEG2-NH2 hydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.



Purity: 96.08%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg, 500 mg

(S,R,S)-AHPC-PEG3-N3 (VH032-PEG3-N3; VHL Ligand-Linker Conjugates 8; E3 ligase Ligand-Linker Conjugates 12) Cat. No.: HY-103598


(S,R,S)-AHPC-PEG3-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 500 mg

(S,R,S)-AHPC-PEG3-NH2 (VH032-PEG3-NH2; VHL Ligand-Linker Conjugates 1; ...) Cat. No.: HY-103602A


(S,R,S)-AHPC-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg, 500 mg

(S,R,S)-AHPC-PEG3-NH2 hydrochloride (VH032-PEG3-NH2 hydrochloride; ...) Cat. No.: HY-103602


(S,R,S)-AHPC-PEG3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-PEG3-propionic acid Cat. No.: HY-136165


(S,R,S)-AHPC-PEG3-propionic acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-PEG4-N3 (VH032-PEG4-N3; VHL Ligand-Linker Conjugates 5; E3 ligase Ligand-Linker Conjugates 4) Cat. No.: HY-103601

(S,R,S)-AHPC-PEG4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.




Purity: 98.77%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-PEG4-NH2 (VH032-PEG4-NH2; VHL Ligand-Linker

Conjugates 4; ...)

Cat. No.: HY-103604A

(S,R,S)-AHPC-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.




Purity: 99.51%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-PEG4-NH2 hydrochloride (VH032-PEG4-NH2 hydrochloride; ...)

Cat. No.: HY-103604

(S,R,S)-AHPC-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-PEG5-Boc

Cat. No.: HY-131959

(S,R,S)-AHPC-PEG5-Boc is a E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for Cdc20 degrader CP5V.




Purity: 95.29%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

(S,R,S)-AHPC-PEG5-COOH (VH032-PEG5-COOH; VHL Ligand-Linker

Conjugates 16; E3 Ligase Ligand-Linker Conjugates 58)

Cat. No.: HY-130271

(S,R,S)-AHPC-PEG5-COOH (VH032-PEG5-COOH) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 5-unit PEG linker used in PROTAC technology.



Purity: 95.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

(S,R,S)-AHPC-PEG6-C4-Cl (VH032-PEG6-C4-Cl; VHL Ligand-Linker

Conjugates 10; E3 ligase Ligand-Linker Conjugates 9)

Cat. No.: HY-103606

(S,R,S)-AHPC-PEG6-C4-Cl is a conjugate of ligands for E3 and 25-atom-length linker. The connector of linker is Halogen group. (S,R,S)-AHPC-PEG6-C4-Cl incorporates the (S,R,S)-AHPC based VHL ligand and 6-unit PEG linker.




Purity: 98.07%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-phenol-alkylC6-amine dihydrochloride

(VH032 phenol-alkylC6-amine dihydrochloride)

Cat. No.: HY-136183

(S,R,S)-AHPC-phenol-alkylC6-amine dihydrochloride is a synthesized **E3 ligase ligand-linker conjugate** that incorporates the VH032 based VHL ligand and an alkyl linker used for PROTAC degrader.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S,R,S)-AHPC-phenol-C4-NH2 dihydrochloride

(VH032-phenol-C4-NH2 dihydrochloride)

Cat. No.: HY-136184

(S,R,S)-AHPC-phenol-C4-NH2 (VH032-phenol-C4-NH2) dihydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2-(2,6-Dioxopiperidin-3-yl)phthalimidine-C5-Br

Cat. No.: HY-132939

2-(2,6-Dioxopiperidin-3-yl)phthalimidine-C5-Br is a E3 ligase ligand-linker conjugate for PROTAC.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

A 410099.1 amide-PEG2-amine-Boc

Cat. No.: HY-136273

A 410099.1 amide-PEG2-amine-Boc is a functionalized IAP ligand for PROTACs that incorporates an IAP ligand and an amide-PEG3 linker with terminal amine. A 410099.1 amide-PEG2-amine-Boc can conjugates with target protein ligands.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg











A 410099.1 amide-PEG3-amine-Boc

Cat. No.: HY-136272

A 410099.1 amide-PEG3-amine-Boc is a functionalized IAP ligand for PROTACs that incorporates an IAP ligand and an amide-PEG3 linker with terminal amine. A 410099.1 amide-PEG3-amine-Boc can conjugates with target protein ligands.













Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

<p>A 410099.1, amine-Boc</p> <p style="text-align: right;">Cat. No.: HY-136269A</p>	<p>A 410099.1, amine-Boc hydrochloride</p> <p style="text-align: right;">Cat. No.: HY-136269</p>
<p>A 410099.1, amine-Boc is a functionalized IAP ligand and can be used for the synthesis of PROTACs, such as PROTACs targeting BTK (PROTACs 4 and 5).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>A 410099.1, amine-Boc hydrochloride is a functionalized IAP ligand and can be used for the synthesis of PROTACs, such as PROTACs targeting BTK (PROTACs 4 and 5).</p>  <p>Purity: 95.03% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>AhR Ligand-Linker Conjugates 1 (E3 Ligase Ligand-Linker Conjugates 57)</p> <p style="text-align: right;">Cat. No.: HY-130270</p>	<p>Boc-A 410099.1 amide-alkylC4-amine</p> <p style="text-align: right;">Cat. No.: HY-136274</p>
<p>AhR Ligand-Linker Conjugates 1 (E3 Ligase Ligand-Linker Conjugates 57) incorporates an IAP ligand for the E3 ubiquitin ligase, and a SNIPER linker. AhR Ligand-Linker Conjugates 1 can be used to design SNIPER.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Boc-A 410099.1 amide-alkylC4-amine is a functionalized IAP ligand for PROTACs that incorporates an IAP ligand and an amide-alkylC4 linker with terminal amine. Boc-A 410099.1 amide-alkylC4-amine can conjugates with target protein ligands.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>cIAP1 Ligand-Linker Conjugates 1 (E3 ligase Ligand-Linker Conjugates 41)</p> <p style="text-align: right;">Cat. No.: HY-128820</p>	<p>cIAP1 Ligand-Linker Conjugates 10 (E3 ligase Ligand-Linker Conjugates 47)</p> <p style="text-align: right;">Cat. No.: HY-128826</p>
<p>cIAP1 Ligand-Linker Conjugates 1 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 1 can be used to design SNIPERs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 10 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 10 can be used to design SNIPERs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>
<p>cIAP1 Ligand-Linker Conjugates 11 (E3 ligase Ligand-Linker Conjugates 33)</p> <p style="text-align: right;">Cat. No.: HY-128812</p>	<p>cIAP1 Ligand-Linker Conjugates 11 Hydrochloride (E3 ligase Ligand-Linker Conjugates 33 Hydrochloride)</p> <p style="text-align: right;">Cat. No.: HY-128812A</p>
<p>cIAP1 Ligand-Linker Conjugates 11 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 11 can be used to design SNIPERs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 11 Hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 11 Hydrochloride can be used to design SNIPERs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>
<p>cIAP1 Ligand-Linker Conjugates 12 (E3 ligase Ligand-Linker Conjugates 38)</p> <p style="text-align: right;">Cat. No.: HY-128817</p>	<p>cIAP1 Ligand-Linker Conjugates 13 (E3 ligase Ligand-Linker Conjugates 43)</p> <p style="text-align: right;">Cat. No.: HY-128822</p>
<p>cIAP1 Ligand-Linker Conjugates 12 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 12 can be used to design SNIPERs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 13 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 13 can be used to design SNIPERs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>

<p>cIAP1 Ligand-Linker Conjugates 14 (E3 ligase Ligand-Linker Conjugates 36)</p>	<p>cIAP1 Ligand-Linker Conjugates 15 (E3 ligase Ligand-Linker Conjugates 34)</p>
<p>cIAP1 Ligand-Linker Conjugates 14 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 14 can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 15 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 15 can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>
<p>cIAP1 Ligand-Linker Conjugates 15 hydrochloride (E3 ligase Ligand-Linker Conjugates 34 hydrochloride)</p>	<p>cIAP1 Ligand-Linker Conjugates 16</p>
<p>cIAP1 Ligand-Linker Conjugates 15 hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 15 hydrochloride can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 16 is an E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACs.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>cIAP1 Ligand-Linker Conjugates 2 (E3 ligase Ligand-Linker Conjugates 37)</p>	<p>cIAP1 Ligand-Linker Conjugates 2 Hydrochloride (E3 ligase Ligand-Linker Conjugates 37 Hydrochloride)</p>
<p>cIAP1 Ligand-Linker Conjugates 2 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 2 can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 2 Hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 2 Hydrochloride can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>
<p>cIAP1 Ligand-Linker Conjugates 3 (E3 ligase Ligand-Linker Conjugates 40)</p>	<p>cIAP1 Ligand-Linker Conjugates 4 (E3 ligase Ligand-Linker Conjugates 42)</p>
<p>cIAP1 Ligand-Linker Conjugates 3 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 3 can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 4 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 4 can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>
<p>cIAP1 Ligand-Linker Conjugates 5 (E3 ligase Ligand-Linker Conjugates 39)</p>	<p>cIAP1 Ligand-Linker Conjugates 6 hydrochloride (E3 ligase Ligand-Linker Conjugates 35 hydrochloride)</p>
<p>cIAP1 Ligand-Linker Conjugates 5 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 5 can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 6 hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 6 hydrochloride can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>


<p>cIAP1 Ligand-Linker Conjugates 7 (E3 ligase Ligand-Linker Conjugates 44)</p>	<p>cIAP1 Ligand-Linker Conjugates 8 (E3 ligase Ligand-Linker Conjugates 46)</p>
<p>cIAP1 Ligand-Linker Conjugates 7 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 7 can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>cIAP1 Ligand-Linker Conjugates 8 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 8 can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>
<p>cIAP1 Ligand-Linker Conjugates 9 (E3 ligase Ligand-Linker Conjugates 45)</p>	<p>EN219-O-C4-NH2 TFA</p>
<p>cIAP1 Ligand-Linker Conjugates 9 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugate 9 can be used to design SNIPERS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 g, 2 g</p>	<p>EN219-O-C4-NH2 TFA incorporates an E3 ubiquitin ligase ligand, and a PROTAC linker. EN219-O-C4-NH2 TFA can be used to design PROTACS.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Glutarimide-Isoindolinone-NH-PEG2-COOH</p>	<p>Glutarimide-Isoindolinone-NH-PEG3-COOH</p>
<p>Glutarimide-Isoindolinone-NH-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates a cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 98.51% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Glutarimide-Isoindolinone-NH-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates a cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 99.12% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>
<p>Glutarimide-Isoindolinone-NH-PEG4-COOH</p>	<p>Lenalidomide-acetylene-C5-COOH (Cereblon ligand-linker Conjugate)</p>
<p>Glutarimide-Isoindolinone-NH-PEG4-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates a cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 99.52% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Lenalidomide-acetylene-C5-COOH (compound 43; Cereblon ligand-linker Conjugate) is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-acetylene-C5-COOH can be connected to the ligand for protein by a linker to form PROTAC.</p> <p>Purity: 98.32% Clinical Data: No Development Reported Size: 10 mg, 25 mg, 50 mg, 100 mg, 500 mg</p>
<p>Lenalidomide-C4-NH2 hydrochloride (Cereblon ligand 1 hydrochloride; ...)</p>	<p>Lenalidomide-C5-amido-Boc</p>
<p>Lenalidomide-C4-NH2 hydrochloride is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein.</p> <p>Purity: 98.85% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>	<p>Lenalidomide-C5-amido-Boc is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C5-amido-Boc can be connected to the ligand for protein by a linker to form PROTAC.</p> <p>Purity: 95.10% Clinical Data: No Development Reported Size: 100 mg, 500 mg</p>

<p>Lenalidomide-C5-NH2 hydrochloride</p> <p>Cat. No.: HY-122725B</p>	<p>Lenalidomide-C5-NH2 TFA</p> <p>Cat. No.: HY-122725A</p>
<p>Lenalidomide-C5-NH2 hydrochloride is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C5-NH2 can be connected to the ligand for protein by a linker to form PROTACs, such as MDM2 PROTAC degrader.</p> <p>Purity: 98.45%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 100 mg, 500 mg</p>	<p>Lenalidomide-C5-NH2 is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C5-NH2 can be connected to the ligand for protein by a linker to form PROTACs, such as MDM2 PROTAC degrader.</p> <p>Purity: 98.94%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg</p>
<p>Lenalidomide-PEG1-azide</p> <p>Cat. No.: HY-133139</p>	<p>Lenalidomide-PEG3-iodine</p> <p>Cat. No.: HY-130982</p>
<p>Lenalidomide-PEG1-azide is a E3 ligase ligand-linker conjugate. Lenalidomide-PEG1-azide incorporates the Lenalidomide based cereblon ligand and a linker.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Lenalidomide-PEG3-iodine is a synthesized E3 ligase ligand-linker conjugate that incorporates the Lenalidomide based cereblon ligand and a 3-unit PEG linker. Lenalidomide-PEG3-iodine can be used in the synthesis of a series of PROTACs, such as SJF620 (HY-133137).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 50 mg</p>
<p>Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride</p> <p>Cat. No.: HY-130682</p>	<p>Lenalidomide-propargyl-C2-NH2 hydrochloride</p> <p>Cat. No.: HY-130683</p>
<p>Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase and a linker. Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride can be used to design the PROTAC MD-224 (HY-114312).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Lenalidomide-propargyl-C2-NH2 hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase, and a linker. Lenalidomide-propargyl-C2-NH2 hydrochloride can be used to design the PROTAC MD-224 (HY-114312).</p> <p>Purity: 99.08%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>N-Boc-SBP-0636457-O-C3-COOH</p> <p>Cat. No.: HY-131190</p>	<p>N-Descyclopropanecarbaldehyde Olaparib</p> <p>Cat. No.: HY-75706</p>
<p>N-Boc-SBP-0636457-OH is a synthesized E3 ligase ligand-linker conjugate that incorporates IAP ligand and a linker. N-Boc-SBP-0636457-OH can be used to design a PROTAC Bcl-xL degrader-1 (HY-131188).</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a CRBN-based ligand for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4.</p> <p>Purity: 99.27%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mM × 1 mL, 250 mg</p>
<p>NJH-2-030</p> <p>Cat. No.: HY-143348</p>	<p>Nutlin-C1-amido-PEG4-C2-N3 (MDM2 Ligand-Linker Conjugates 1; E3 ligase Ligand-Linker Conjugates 48)</p> <p>Cat. No.: HY-128832</p>
<p>NJH-2-030 can be used as a covalent recruiter for FEM1B in targeted protein degradation applications.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Nutlin-C1-amido-PEG4-C2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Nutlin 3 based MDM2 ligand and 4-unit PEG linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 g, 2 g</p>

<p>Pom-8PEG</p> <p style="text-align: right;">Cat. No.: HY-132288</p>	<p>Pomalidomide 4'-alkylC5-acid</p> <p style="text-align: right;">Cat. No.: HY-130737</p>
<p>Pom-8PEG, an E3 ligase ligand-linker conjugate, incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase and an 8-unit PEG linker. Pom-8PEG can be used in the synthesis of PROTAC, such as IDO1 PROTAC degrader.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Pomalidomide 4'-alkylC5-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a PEG linker used in PROTAC technology.</p>  <p>Purity: 98.78% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Pomalidomide 4'-PEG2-azide</p> <p style="text-align: right;">Cat. No.: HY-132208</p>	<p>Pomalidomide 4'-PEG3-azide</p> <p style="text-align: right;">Cat. No.: HY-130652</p>
<p>Pomalidomide 4'-PEG2-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 99.24% Clinical Data: No Development Reported Size: 25 mg, 50 mg</p>	<p>Pomalidomide 4'-PEG3-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide-based cereblon ligand and a linker. Pomalidomide 4'-PEG3-azide can be used for the synthesis of iRucaparib-TP3 (Compound 3).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg</p>
<p>Pomalidomide 4'-PEG5-acid (Pomalidomide-PEG5-CO2H)</p> <p style="text-align: right;">Cat. No.: HY-131647</p>	<p>Pomalidomide-amido-C1-Br</p> <p style="text-align: right;">Cat. No.: HY-130617</p>
<p>Pomalidomide 4'-PEG5-acid (Pomalidomide-PEG5-CO2H) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 5-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 95.02% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>	<p>Pomalidomide-amido-C1-Br is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-amido-C1-Br can be used to design a B-Raf PROTAC degrader PROTAC B-Raf degrader 1 (HY-111758).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 50 mg, 100 mg</p>
<p>Pomalidomide-amido-C3-COOH</p> <p style="text-align: right;">Cat. No.: HY-131185</p>	<p>Pomalidomide-amido-C3-piperazine-N-Boc</p> <p style="text-align: right;">Cat. No.: HY-131186</p>
<p>Pomalidomide-amido-C3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 98.22% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Pomalidomide-amido-C3-piperazine-N-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in the synthesis of PROTAC PD-1/PD-L1 degrader-1 (HY-131183).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Pomalidomide-amido-C4-amido-C6-NH-Boc (Cereblon Ligand-Linker Conjugates 21; E3 Ligase Ligand-Linker Conjugates 54)</p> <p style="text-align: right;">Cat. No.: HY-125884</p>	<p>Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc (Cereblon Ligand-Linker Conjugates 20; ...)</p> <p style="text-align: right;">Cat. No.: HY-125883</p>
<p>Pomalidomide-amido-C4-amido-C6-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Pomalidomide-amido-C4-amido-PEG2-C2-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

Pomalidomide-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 22; E3 ligase Ligand-Linker Conjugates 55) Cat. No.: HY-130521


Pomalidomide-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 22) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pomalidomide-amino-PEG3-NH2 Cat. No.: HY-133817A


Pomalidomide-amino-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pomalidomide-amino-PEG3-NH2 hydrochloride Cat. No.: HY-133817

Pomalidomide-amino-PEG3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg

Pomalidomide-amino-PEG4-NH2 Cat. No.: HY-138859


Pomalidomide-amino-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Pomalidomide-amino-PEG4-NH2 hydrochloride Cat. No.: HY-138859A


Pomalidomide-amino-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Pomalidomide-amino-PEG5-NH2 Cat. No.: HY-133816A


Pomalidomide-amino-PEG5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pomalidomide-amino-PEG5-NH2 hydrochloride Cat. No.: HY-133816


Pomalidomide-amino-PEG5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH (Cereblon Ligand-Linker Conjugates 14; ...) Cat. No.: HY-128848


Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.



Purity: 95.02%
Clinical Data: No Development Reported
Size: 100 mg

Pomalidomide-C2-NH2 (Cereblon Ligand-Linker Conjugates 15) Cat. No.: HY-128846


Pomalidomide-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a PEG linker used in PROTAC technology.













Purity: >98%
Clinical Data: No Development Reported
Size: 1 g, 2 g

Pomalidomide-C2-NH2 hydrochloride (Cereblon Ligand-Linker Conjugates 15 hydrochloride) Cat. No.: HY-128846A

Pomalidomide-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.



Purity: 96.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

<p>Pomalidomide-C3-NH2</p> <p>Cat. No.: HY-131888A</p> <p>Pomalidomide-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>Pomalidomide-C3-NH2 hydrochloride</p> <p>Cat. No.: HY-131888</p> <p>Pomalidomide-C3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>Pomalidomide-C4-NH2</p> <p>Cat. No.: HY-138845</p> <p>Pomalidomide-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>Pomalidomide-C4-NH2 hydrochloride</p> <p>Cat. No.: HY-138845A</p> <p>Pomalidomide-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>Pomalidomide-C7-COOH</p> <p>Cat. No.: HY-133799</p> <p>Pomalidomide-C7-COOH is a synthesized E3 ligase cereblon ligand-linker conjugate. Pomalidomide-C7-COOH is an intermediate for the synthesis of PROTAC BCL-XL degraders.</p> <p>Purity: 98.04% Clinical Data: No Development Reported Size: 25 mg, 100 mg, 500 mg</p> 	<p>Pomalidomide-PEG1-azide</p> <p>Cat. No.: HY-133138</p> <p>Pomalidomide-PEG1-azide is a E3 ligase ligand-linker conjugate. Pomalidomide-PEG1-azide incorporates the Pomalidomide based cereblon ligand and a linker.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>Pomalidomide-PEG1-C2-COOH</p> <p>Cat. No.: HY-137531</p> <p>Pomalidomide-PEG1-C2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 1-unit PEG linker used in PROTAC technology.</p> <p>Purity: 99.88% Clinical Data: No Development Reported Size: 25 mg</p> 	<p>Pomalidomide-PEG1-C2-N3 (Cereblon Ligand-Linker Conjugates 13; E3 ligase Ligand-Linker Conjugates 50)</p> <p>Cat. No.: HY-125843</p> <p>Pomalidomide-PEG1-C2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 1-unit PEG linker used in PROTAC technology. Pomalidomide-PEG1-C2-N3 can be used to design a selective CDK6 PROTAC degrader CP-10.</p> <p>Purity: 99.65% Clinical Data: No Development Reported Size: 25 mg</p> 
<p>Pomalidomide-PEG2-azide</p> <p>Cat. No.: HY-137537</p> <p>Pomalidomide-PEG2-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.</p> <p>Purity: 95.01% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 500 mg</p> 	<p>Pomalidomide-PEG2-COOH (Pomalidomide 4'-PEG2-acid)</p> <p>Cat. No.: HY-131872</p> <p>Pomalidomide-PEG2-COOH (Pomalidomide 4'-PEG2-acid) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.</p> <p>Purity: 99.87% Clinical Data: No Development Reported Size: 25 mg, 50 mg</p> 

<p>Pomalidomide-PEG2-Tos</p> <p>Cat. No.: HY-130295</p>	<p>Pomalidomide-PEG3-azide</p> <p>Cat. No.: HY-137538</p>
<p>Pomalidomide-PEG2-Tos is an E3 ligase ligand-linker conjugates, composed of a cereblon ligand and two-unit PEG linker.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Pomalidomide-PEG3-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 98.44%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 50 mg, 100 mg, 500 mg</p>
<p>Pomalidomide-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 5; E3 ligase Ligand-Linker Conjugates 30)</p> <p>Cat. No.: HY-128716</p>	<p>Pomalidomide-PEG3-C2-NH2 hydrochloride (Cereblon Ligand-Linker Conjugates 5 hydrochloride; ...)</p> <p>Cat. No.: HY-128716B</p>
<p>Pomalidomide-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 g, 2 g</p>	<p>Pomalidomide-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 5) hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Pomalidomide-PEG3-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 5 TFA; ...)</p> <p>Cat. No.: HY-128716A</p>	<p>Pomalidomide-PEG4-azide</p> <p>Cat. No.: HY-141015</p>
<p>Pomalidomide-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 99.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg, 1 g, 2 g</p>	<p>Pomalidomide-PEG4-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 96.05%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 250 mg</p>
<p>Pomalidomide-PEG4-C-COOH (Cereblon Ligand -Linker Conjugates 1; E3 Ligase Ligand-Linker Conjugates 1)</p> <p>Cat. No.: HY-21930</p>	<p>Pomalidomide-PEG4-C2-NH2 (Cereblon Ligand-Linker Conjugates 8; E3 Ligase Ligand-Linker Conjugates 22)</p> <p>Cat. No.: HY-112599</p>
<p>Pomalidomide-PEG4-C-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 99.10%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg, 1 g, 2 g</p>	<p>Pomalidomide-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 95.11%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg, 1 g, 2 g</p>
<p>Pomalidomide-PEG4-C2-NH2 hydrochloride</p> <p>Cat. No.: HY-112599B</p>	<p>Pomalidomide-PEG4-Ph-NH2 (Cereblon Ligand-Linker Conjugates 9; E3 Ligase Ligand-Linker Conjugates 2)</p> <p>Cat. No.: HY-41549</p>
<p>Pomalidomide-PEG4-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in the synthesis of PROTACs.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg</p>	<p>Pomalidomide-PEG4-Ph-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology.</p>  <p>Purity: ≥98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg, 1 g, 2 g</p>

Pomalidomide-PEG6-butyl iodide

Cat. No.: HY-136156

Pomalidomide-PEG6-butyl iodide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 6-unit PEG linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pomalidomide-PEG6-NH2 hydrochloride

Cat. No.: HY-136161

Pomalidomide-PEG6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 6-unit PEG linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide 4'-ether-alkylC2-amine

Cat. No.: HY-136162A

Thalidomide 4'-ether-alkylC2-amine is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide 4'-ether-alkylC2-amine hydrochloride

Cat. No.: HY-136162

Thalidomide 4'-ether-alkylC2-amine hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide 4'-oxacetamide-alkyl-C2-amine hydrochloride

Cat. No.: HY-136160

Thalidomide 4'-oxacetamide-alkyl-C2-amine hydrochloride incorporates a cereblon (CRBN) ligand for the E3 ubiquitin ligase, and a linker. Thalidomide 4'-oxacetamide-alkyl-C2-amine hydrochloride can be used to design the PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-4-O-C10-COOH

Cat. No.: HY-132858

Thalidomide-4-O-C10-COOH is a E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACs.




Purity: 98.86%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Thalidomide-5-PEG3-NH2

Cat. No.: HY-138786

Thalidomide-5-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-5-PEG4-NH2

Cat. No.: HY-138785

Thalidomide-5-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-amido-PEG2-NH2

Cat. No.: HY-138858

Thalidomide-amido-PEG2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-amido-PEG2-NH2 hydrochloride

Cat. No.: HY-138858A

Thalidomide-amido-PEG2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

<p>Thalidomide-C2-amido-C2-COOH</p> <p>Cat. No.: HY-130713</p>	<p>Thalidomide-NH-amido-C2-NH2</p> <p>Cat. No.: HY-138849</p>
<p>Thalidomide-C2-amido-C2-COOH incorporates a CRBN ligand for the E3 ubiquitin ligase, and a linker. Thalidomide-C2-amido-C2-COOH can be used to design PROTAC CDK2/9 Degradator-1 (HY-130709).</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-amido-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-amido-C2-NH2 hydrochloride</p> <p>Cat. No.: HY-138849A</p>	<p>Thalidomide-NH-amido-C3-NH2</p> <p>Cat. No.: HY-138850</p>
<p>Thalidomide-NH-amido-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-amido-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-amido-C3-NH2 hydrochloride</p> <p>Cat. No.: HY-138850A</p>	<p>Thalidomide-NH-amido-C4-NH2</p> <p>Cat. No.: HY-134984</p>
<p>Thalidomide-NH-amido-C3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-amido-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-amido-C4-NH2 hydrochloride</p> <p>Cat. No.: HY-134984A</p>	<p>Thalidomide-NH-amido-C5-NH2</p> <p>Cat. No.: HY-138851</p>
<p>Thalidomide-NH-amido-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-amido-C5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-amido-C5-NH2 hydrochloride</p> <p>Cat. No.: HY-138851A</p>	<p>Thalidomide-NH-amido-C6-NH2</p> <p>Cat. No.: HY-138852</p>
<p>Thalidomide-NH-amido-C5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-amido-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

Thalidomide-NH-amido-C6-NH2 hydrochloride

Cat. No.: HY-138852A

Thalidomide-NH-amido-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-NH-amido-C8-NH2

Cat. No.: HY-138853

Thalidomide-NH-amido-C8-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-NH-amido-C8-NH2 hydrochloride

Cat. No.: HY-138853A

Thalidomide-NH-amido-C8-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-NH-amido-PEG1-C2-NH2

Cat. No.: HY-138854

Thalidomide-NH-amido-PEG1-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride

Cat. No.: HY-138854A

Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-NH-amido-PEG2-C2-NH2

Cat. No.: HY-138855

Thalidomide-NH-amido-PEG2-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-NH-amido-PEG2-C2-NH2 hydrochloride

Cat. No.: HY-138855A

Thalidomide-NH-amido-PEG2-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-NH-amido-PEG3-C2-NH2

Cat. No.: HY-138856

Thalidomide-NH-amido-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-NH-amido-PEG3-C2-NH2 hydrochloride

Cat. No.: HY-138856A

Thalidomide-NH-amido-PEG3-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-NH-amido-PEG4-C2-NH2

Cat. No.: HY-138857

Thalidomide-NH-amido-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

<p>Thalidomide-NH-amido-PEG4-C2-NH2 hydrochloride</p> <p>Cat. No.: HY-138857A</p>	<p>Thalidomide-NH-C10-COOH</p> <p>Cat. No.: HY-130716</p>
<p>Thalidomide-NH-amido-PEG4-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-C10-COOH (compound 6b) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based von Hippel-Lindau (VHL) ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-C2-PEG3-OH</p> <p>Cat. No.: HY-131308</p>	<p>Thalidomide-NH-C4-NH-Boc</p> <p>Cat. No.: HY-130639</p>
<p>Thalidomide-NH-C2-PEG3-OH is an E3 ligase ligand-linker conjugate that incorporates Thalidomide based cereblon ligand and a linker used for PROTAC BCL-XL degrader XZ739.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-C4-NH-Boc (compound 15) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 99.64%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 50 mg, 100 mg</p>
<p>Thalidomide-NH-C4-NH2 TFA</p> <p>Cat. No.: HY-130814</p>	<p>Thalidomide-NH-C5-NH2</p> <p>Cat. No.: HY-134986</p>
<p>Thalidomide-NH-C4-NH2 TFA (compound 29c) is an E3 ligase ligand-linker conjugate, and incorporates the Thalidomide based cereblon ligand and a linker. Thalidomide-NH-C4-NH2 TFA is used in PROTAC BRD2/BRD4 degrader-1 (HY-130612).</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-C5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-C5-NH2 hydrochloride</p> <p>Cat. No.: HY-136237</p>	<p>Thalidomide-NH-C6-NH-Boc</p> <p>Cat. No.: HY-130854</p>
<p>Thalidomide-NH-C5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: ≥98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 50 mg, 100 mg</p>	<p>Thalidomide-NH-C6-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used for MI-389 (compound 22) synthesis.</p>  <p>Purity: 96.11%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 250 mg</p>
<p>Thalidomide-NH-C6-NH2</p> <p>Cat. No.: HY-129704</p>	<p>Thalidomide-NH-C6-NH2 hydrochloride</p> <p>Cat. No.: HY-129704B</p>
<p>Thalidomide-NH-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>

Thalidomide-NH-C6-NH2 TFA

Cat. No.: HY-129704A

Thalidomide-NH-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 250 mg, 500 mg

Thalidomide-NH-C8-NH2

Cat. No.: HY-138846

Thalidomide-NH-C8-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-NH-C8-NH2 hydrochloride

Cat. No.: HY-138846A

Thalidomide-NH-C8-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-NH-PEG1-NH2

Cat. No.: HY-134985

Thalidomide-NH-PEG1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-NH-PEG1-NH2 hydrochloride

Cat. No.: HY-131867

Thalidomide-NH-PEG1-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-NH-PEG2-C2-NH-Boc

Cat. No.: HY-130853

Thalidomide-NH-PEG2-C2-NH-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a PEG linker used for dBRD9 (compound 6) synthesis.




Purity: 98.17%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

Thalidomide-NH-PEG2-COOH

Cat. No.: HY-138772

Thalidomide-NH-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: 98.74%
Clinical Data: No Development Reported
Size: 100 mg

Thalidomide-NH-PEG3-COOH

Cat. No.: HY-138771

Thalidomide-NH-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: 98.33%
Clinical Data: No Development Reported
Size: 50 mg

Thalidomide-NH-PEG3-propionic acid

Cat. No.: HY-136166

Thalidomide-NH-PEG3-propionic acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.




Purity: 99.72%
Clinical Data: No Development Reported
Size: 25 mg, 100 mg









Thalidomide-NH-PEG4-COOH

Cat. No.: HY-134591

Thalidomide-NH-PEG4-COOH is an E3 ligase ligand-linker conjugate which can be used for synthesizing dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP.




Purity: 98.55%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

<p>Thalidomide-NH-PEG4-Ms</p> <p style="text-align: right;">Cat. No.: HY-131998</p>	<p>Thalidomide-NH-PEG7</p> <p style="text-align: right;">Cat. No.: HY-130648</p>
<p>Thalidomide-NH-PEG4-Ms is an E3 ligase ligand-linker conjugate that incorporates Thalidomide based cereblon ligand and a linker used for PROTAC BCL-XL degrader XZ739.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-NH-PEG7 is a synthesized E3 ligase ligand-linker conjugate for ADC. Thalidomide-NH-PEG7 can be connected to the ligand for protein by a linker to form PROTAC iRucaparib-AP6, a highly specific PARP1 degrader.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-NH-PEG8-Ts</p> <p style="text-align: right;">Cat. No.: HY-131912</p>	<p>Thalidomide-O-amide-C5-NH2</p> <p style="text-align: right;">Cat. No.: HY-141423</p>
<p>Thalidomide-NH-PEG8-Ts is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 8-unit PEG linker used in PROTAC technology, such as IDO1 PROTAC degrader (HY-131911).</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-amide-C5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 50 mg, 100 mg</p>
<p>Thalidomide-O-amide-C5-NH2 TFA</p> <p style="text-align: right;">Cat. No.: HY-141423A</p>	<p>Thalidomide-O-amido-C3-COOH (Cereblon Ligand-Linker Conjugates 7; E3 ligase Ligand-Linker Conjugates 15)</p> <p style="text-align: right;">Cat. No.: HY-103612</p>
<p>Thalidomide-O-amide-C5-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-amido-C3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 99.49%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg, 1 g, 2 g</p>
<p>Thalidomide-O-amido-C3-NH2 (Cereblon Ligand-Linker Conjugates 16; E3 Ligase Ligand-Linker Conjugates 52)</p> <p style="text-align: right;">Cat. No.: HY-115560</p>	<p>Thalidomide-O-amido-C3-NH2 TFA (Cereblon Ligand-Linker Conjugates 16 TFA; ...)</p> <p style="text-align: right;">Cat. No.: HY-115560A</p>
<p>Thalidomide-O-amido-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-amido-C3-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 98.18%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 50 mg</p>
<p>Thalidomide-O-amido-C3-PEG3-C1-NH2</p> <p style="text-align: right;">Cat. No.: HY-131646</p>	<p>Thalidomide-O-amido-C4-N3 (Cereblon Ligand-Linker Conjugates 4; E3 ligase Ligand-Linker Conjugates 18)</p> <p style="text-align: right;">Cat. No.: HY-103615</p>
<p>Thalidomide-O-amido-C3-PEG3-C1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 99.48%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 50 mg, 100 mg</p>	<p>Thalidomide-O-amido-C4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 98.63%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg, 1 g, 2 g</p>

Thalidomide-O-amido-C4-NH2 (Cereblon Ligand-Linker Conjugates 6; E3 Ligase Ligand-Linker Conjugates 19)

Cat. No.: HY-107438

Thalidomide-O-amido-C4-NH2 (Cereblon Ligand-Linker Conjugates 6), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-amido-C4-NH2 hydrochloride

Cat. No.: HY-107438A

Thalidomide-O-amido-C4-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.




Purity: 98.11%
Clinical Data: No Development Reported
Size: 25 mg, 100 mg

Thalidomide-O-amido-C4-NH2 TFA (Cereblon Ligand-Linker Conjugates 6 TFA; ...)

Cat. No.: HY-103613

Thalidomide-O-amido-C4-NH2 TFA (Cereblon Ligand-Linker Conjugates 6 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: 99.74%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

Thalidomide-O-amido-C6-NH2 (Cereblon Ligand-Linker Conjugates 11; E3 Ligase Ligand-Linker Conjugates 25)

Cat. No.: HY-112618

Thalidomide-O-amido-C6-NH2 (Cereblon Ligand-Linker Conjugates 11), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-amido-C6-NH2 hydrochloride

Cat. No.: HY-112618B

Thalidomide-O-amido-C6-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA; ...)

Cat. No.: HY-112618A

Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.




Purity: 99.82%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

Thalidomide-O-amido-C8-NH2 (Cereblon Ligand-Linker Conjugates 2; E3 Ligase Ligand-Linker Conjugates 20)

Cat. No.: HY-107439

Thalidomide-O-amido-C8-NH2 (Cereblon Ligand-Linker Conjugates 2), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-amido-C8-NH2 hydrochloride

Cat. No.: HY-107439A

Thalidomide-O-amido-C8-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-amido-C8-NH2 TFA (Cereblon Ligand-Linker Conjugates 2 TFA; ...)

Cat. No.: HY-103614

Thalidomide-O-amido-C8-NH2 TFA (Cereblon Ligand-Linker Conjugates 2 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: 99.11%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc











Cat. No.: HY-145177

Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc is a synthesized E3 ligase ligand-linker conjugate. Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc incorporates the Thalidomide based cereblon ligand and a linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

<p>Thalidomide-O-amido-PEG-C2-NH2</p> <p>Cat. No.: HY-122694</p>	<p>Thalidomide-O-amido-PEG-C2-NH2 hydrochloride</p> <p>Cat. No.: HY-122694A</p>
<p>Thalidomide-O-amido-PEG-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 50 mg, 100 mg</p>	<p>Thalidomide-O-amido-PEG-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.</p>  <p>Purity: 98.54%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg</p>
<p>Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 (Cereblon Ligand-Linker Conjugates 12; ...)</p> <p>Cat. No.: HY-112600</p>	<p>Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 12 TFA; ...)</p> <p>Cat. No.: HY-112600A</p>
<p>Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 99.28%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 50 mg, 100 mg</p>
<p>Thalidomide-O-amido-PEG2-C2-NH2 (Cereblon Ligand-Linker Conjugates 10; E3 Ligase Ligand-Linker Conjugates 24)</p> <p>Cat. No.: HY-112617</p>	<p>Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride</p> <p>Cat. No.: HY-112617B</p>
<p>Thalidomide-O-amido-PEG2-C2-NH2 incorporates an E3 ligase ligand and a linker, can be an immunomodulator for the treatment of cancer.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride incorporates an E3 ligase ligand and a linker, can be an immunomodulator for the treatment of cancer.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-O-amido-PEG2-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 10 TFA; ...)</p> <p>Cat. No.: HY-112617A</p>	<p>Thalidomide-O-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 3 ; E3 Ligase Ligand-Linker Conjugates 14)</p> <p>Cat. No.: HY-107440</p>
<p>Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 99.52%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg, 1 g, 2 g</p>	<p>Thalidomide-O-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 3) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride</p> <p>Cat. No.: HY-107440A</p>	<p>Thalidomide-O-amido-PEG3-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 3 TFA; ...)</p> <p>Cat. No.: HY-103611</p>
<p>Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 98.29%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 100 mg</p>	<p>Thalidomide-O-amido-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.</p>  <p>Purity: 99.55%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 500 mg, 1 g, 2 g</p>


<p>Thalidomide-O-amido-PEG4-C2-NH2</p> <p>Cat. No.: HY-122710</p>	<p>Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride</p> <p>Cat. No.: HY-122710A</p>
<p>Thalidomide-O-amido-PEG4-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-amido-PEG4-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-O-C10-NH2</p> <p>Cat. No.: HY-130963</p>	<p>Thalidomide-O-C11-acid</p> <p>Cat. No.: HY-138860</p>
<p>Thalidomide-O-C10-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-C11-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-O-C2-acid</p> <p>Cat. No.: HY-131880</p>	<p>Thalidomide-O-C3-acid</p> <p>Cat. No.: HY-131876</p>
<p>Thalidomide-O-C2-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 95.76% Clinical Data: No Development Reported Size: 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Thalidomide-O-C3-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg</p>
<p>Thalidomide-O-C3-NH2</p> <p>Cat. No.: HY-138847</p>	<p>Thalidomide-O-C3-NH2 hydrochloride</p> <p>Cat. No.: HY-138847A</p>
<p>Thalidomide-O-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-C3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-O-C4-COOH</p> <p>Cat. No.: HY-130950</p>	<p>Thalidomide-O-C4-NH2</p> <p>Cat. No.: HY-130948</p>
<p>Thalidomide-O-C4-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>	<p>Thalidomide-O-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>

<p>Thalidomide-O-C4-NH2 hydrochloride</p> <p>Cat. No.: HY-130948B</p>	<p>Thalidomide-O-C5-acid</p> <p>Cat. No.: HY-131889</p>
<p>Thalidomide-O-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide (HY-14658) based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-C5-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 96.24%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg</p>
<p>Thalidomide-O-C5-NH2</p> <p>Cat. No.: HY-138848</p>	<p>Thalidomide-O-C5-NH2 hydrochloride</p> <p>Cat. No.: HY-138848A</p>
<p>Thalidomide-O-C5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-C5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-O-C6-COOH</p> <p>Cat. No.: HY-130951</p>	<p>Thalidomide-O-C6-NH2</p> <p>Cat. No.: HY-135250</p>
<p>Thalidomide-O-C6-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-C6-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-O-C6-NH2 hydrochloride</p> <p>Cat. No.: HY-135250B</p>	<p>Thalidomide-O-C6-NH2 TFA</p> <p>Cat. No.: HY-135250A</p>
<p>Thalidomide-O-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12^{F36V} and BET.</p> <p>Purity: 98.53%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg</p>	<p>Thalidomide-O-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13 (HY-114421), a degrader of FKBP12^{F36V} and BET.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-O-C6-NHBoc</p> <p>Cat. No.: HY-141887</p>	<p>Thalidomide-O-C7-acid</p> <p>Cat. No.: HY-131874</p>
<p>Thalidomide-O-C6-NHBoc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-O-C7-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>

Thalidomide-O-C7-NH2

Cat. No.: HY-130949

Thalidomide-O-C7-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

Thalidomide-O-C8-NH2

Cat. No.: HY-133485

Thalidomide-O-C8-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-C8-NH2 hydrochloride

Cat. No.: HY-133485B

Thalidomide-O-C8-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-PEG2-propargyl (E3 ligase Ligand-Linker Conjugates 32)

Cat. No.: HY-126458

Thalidomide-O-PEG2-propargyl (E3 ligase Ligand-Linker Conjugates 32) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.




Purity: 97.57%
Clinical Data: No Development Reported
Size: 25 mg, 100 mg

Thalidomide-O-PEG4-amine

Cat. No.: HY-141010

Thalidomide-O-PEG4-amine is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-PEG4-amine hydrochloride

Cat. No.: HY-141010A

Thalidomide-O-PEG4-amine hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-PEG4-amine TFA

Cat. No.: HY-141010B

Thalidomide-O-PEG4-amine TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

Thalidomide-O-PEG4-azide

Cat. No.: HY-140844

Thalidomide-O-PEG4-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-PEG4-Boc

Cat. No.: HY-141014

Thalidomide-O-PEG4-Boc is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Thalidomide-O-PEG4-NHS ester

Cat. No.: HY-141012

Thalidomide-O-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.



Purity: 98.23%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

<p>Thalidomide-PEG2-C2-NH2 (Thalidomide-NH-PEG2-C2-NH2)</p>	<p>Thalidomide-PEG2-C2-NH2 hydrochloride (Thalidomide-NH-PEG2-C2-NH2 hydrochloride)</p>
<p>Thalidomide-PEG2-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Thalidomide-PEG2-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-PEG2-C2-NH2 TFA (Thalidomide-NH-PEG2-C2-NH2 TFA)</p>	<p>Thalidomide-PEG2-NH2</p>
<p>Thalidomide-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology.</p> <p>Purity: 98.85% Clinical Data: No Development Reported Size: 25 mg, 100 mg</p>	<p>Thalidomide-PEG2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg</p>
<p>Thalidomide-PEG3-COOH</p>	<p>Thalidomide-PEG3-NH2</p>
<p>Thalidomide-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 98.05% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Thalidomide-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 25 mg, 50 mg, 100 mg</p>
<p>Thalidomide-PEG4-COOH</p>	<p>Thalidomide-PEG4-NH2 hydrochloride</p>
<p>Thalidomide-PEG4-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 95.08% Clinical Data: No Development Reported Size: 100 mg</p>	<p>Thalidomide-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>
<p>Thalidomide-PEG4-Propargyl</p>	<p>Thalidomide-PEG5-COOH</p>
<p>Thalidomide-PEG4-Propargyl is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 50 mg, 100 mg, 250 mg</p>	<p>Thalidomide-PEG5-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 98.09% Clinical Data: No Development Reported Size: 100 mg</p>

<p>Thalidomide-PEG5-NH2</p> <p>Cat. No.: HY-138784</p>	<p>Thalidomide-Piperazine 5-fluoride</p> <p>Cat. No.: HY-134983</p>
<p>Thalidomide-PEG5-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-Piperazine 5-fluoride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-piperazine-Boc</p> <p>Cat. No.: HY-134982</p>	<p>Thalidomide-Piperazine-PEG1-COOH</p> <p>Cat. No.: HY-138782</p>
<p>Thalidomide-piperazine-Boc is an intermediate that can be used in the synthesis of B-cell lymphoma 6 protein (BCL6) PROTAC.</p> <p>Purity: 99.75%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 100 mg, 250 mg</p>	<p>Thalidomide-Piperazine-PEG1-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 99.79%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg</p>
<p>Thalidomide-Piperazine-PEG1-NH2</p> <p>Cat. No.: HY-138789</p>	<p>Thalidomide-Piperazine-PEG1-NH2 diTFA</p> <p>Cat. No.: HY-138789A</p>
<p>Thalidomide-Piperazine-PEG1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>Thalidomide-Piperazine-PEG1-NH2 diTFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 99.84%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 50 mg, 100 mg</p>
<p>Thalidomide-Piperazine-PEG2-COOH</p> <p>Cat. No.: HY-138781</p>	<p>Thalidomide-Piperazine-PEG2-NH2</p> <p>Cat. No.: HY-138788</p>
<p>Thalidomide-Piperazine-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 98.96%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg</p>	<p>Thalidomide-Piperazine-PEG2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>
<p>Thalidomide-Piperazine-PEG2-NH2 diTFA</p> <p>Cat. No.: HY-138788A</p>	<p>Thalidomide-Piperazine-PEG3-COOH</p> <p>Cat. No.: HY-138780</p>
<p>Thalidomide-Piperazine-PEG2-NH2 diTFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 99.76%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 50 mg, 100 mg</p>	<p>Thalidomide-Piperazine-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p> <p>Purity: 99.66%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg</p>


<p>Thalidomide-Piperazine-PEG3-NH2</p> <p>Cat. No.: HY-138787</p>	<p>Thalidomide-Piperazine-Piperidine</p> <p>Cat. No.: HY-138783</p>
<p>Thalidomide-Piperazine-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 50 mg, 100 mg</p>	<p>Thalidomide-Piperazine-Piperidine is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>
<p>Thalidomide-Piperazine-Piperidine hydrochloride</p> <p>Cat. No.: HY-138783A</p>	<p>Thalidomide-Propargyne-PEG1-COOH</p> <p>Cat. No.: HY-138778</p>
<p>Thalidomide-Piperazine-Piperidine hydrochloride is a synthesized E3 ligase ligand-linker conjugate. Thalidomide-Piperazine-Piperidine hydrochloride incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>Thalidomide-Propargyne-PEG1-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 99.45%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 50 mg, 100 mg</p>
<p>Thalidomide-Propargyne-PEG2-COOH</p> <p>Cat. No.: HY-138777</p>	<p>Thalidomide-Propargyne-PEG3-COOH</p> <p>Cat. No.: HY-138776</p>
<p>Thalidomide-Propargyne-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 99.07%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 50 mg, 100 mg</p>	<p>Thalidomide-Propargyne-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.</p>  <p>Purity: 98.01%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 25 mg, 50 mg</p>
<p>VH032-PEG3-acetylene</p> <p>Cat. No.: HY-128767</p>	<p>VH032-PEG5-C6-Cl (HaloPROTAC 2)</p> <p>Cat. No.: HY-112495</p>
<p>VH032-PEG3-acetylene is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.</p>  <p>Purity: 96.57%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p>	<p>VH032-PEG5-C6-Cl (HaloPROTAC 2) is a conjugate of ligands for E3 and 21-atom-length linker. The connector of linker is Halogen group. VH032-PEG5-C6-Cl incorporates the VH032 based VHL ligand and 5-unit PEG linker.</p>  <p>Purity: 99.76%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg</p>
<p>VH032-thiol-C6-NH2 (VHL Ligand-Linker Conjugates 14; E3 ligase Ligand-Linker Conjugates 29)</p> <p>Cat. No.: HY-111824</p>	<p>VH285-PEG4-C4-Cl (HaloPROTAC 3)</p> <p>Cat. No.: HY-111997</p>
<p>VH032-thiol-C6-NH2 (VHL Ligand-Linker Conjugates 14) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>	<p>VH285-PEG4-C4-Cl (HaloPROTAC 3) is a conjugate of ligands for E3 and 16-atom-length linker. The connector of linker is Halogen group. VH285-PEG4-C4-Cl incorporates the VH285 based VHL ligand and an alkyl/ether-based linker.</p>  <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p>

VHL Ligand-Linker Conjugates 15

(E3 Ligase Ligand-Linker Conjugates 56)

Cat. No.: HY-125906

VHL Ligand-Linker Conjugates 15 incorporates an VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. VHL Ligand-Linker Conjugates 15 can be used to design PROTACs.



Purity: >98%


Clinical Data: No Development Reported

Size: 1 mg, 5 mg

VHL Ligand-Linker Conjugates 17

Cat. No.: HY-133046

VHL Ligand-Linker Conjugates 17 incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. VHL Ligand-Linker Conjugates 17 can be used in the synthesis of a series of PROTACs, such as ARD-266 (HY-133020). ARD-266 is a highly potent androgen receptor (AR) PROTAC degrader.



Purity: >98%

Clinical Data: No Development Reported

Size: 1 mg, 5 mg